CA2560282A1 - Crystalline form of atorvastatin hemi calcium - Google Patents

Crystalline form of atorvastatin hemi calcium Download PDF

Info

Publication number
CA2560282A1
CA2560282A1 CA002560282A CA2560282A CA2560282A1 CA 2560282 A1 CA2560282 A1 CA 2560282A1 CA 002560282 A CA002560282 A CA 002560282A CA 2560282 A CA2560282 A CA 2560282A CA 2560282 A1 CA2560282 A1 CA 2560282A1
Authority
CA
Canada
Prior art keywords
atorvastatin hemi
hemi calcium
calcium
atorvastatin
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560282A
Other languages
English (en)
French (fr)
Inventor
Yatendra Kumar
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2560282A1 publication Critical patent/CA2560282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA002560282A 2004-03-17 2005-03-17 Crystalline form of atorvastatin hemi calcium Abandoned CA2560282A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN491/DEL/2004 2004-03-17
IN491DE2004 2004-03-17
IN562DE2005 2005-03-16
IN562/DEL/2005 2005-03-16
PCT/IB2005/000687 WO2005090301A1 (en) 2004-03-17 2005-03-17 Crystalline form of atorvastatin hemi calcium

Publications (1)

Publication Number Publication Date
CA2560282A1 true CA2560282A1 (en) 2005-09-29

Family

ID=34993618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560282A Abandoned CA2560282A1 (en) 2004-03-17 2005-03-17 Crystalline form of atorvastatin hemi calcium

Country Status (4)

Country Link
EP (1) EP1761489A1 (de)
AU (1) AU2005223491A1 (de)
CA (1) CA2560282A1 (de)
WO (1) WO2005090301A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536373A (ja) * 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
EP1771412A2 (de) * 2004-07-20 2007-04-11 Warner-Lambert Company LLC Kristalline formen von [r-(r*)]-2-(4-fluorphenyl)-beta,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-calciumsalz (2:1)
WO2006039441A2 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
AU2006281229A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
AU2006281237A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
RU2421445C1 (ru) * 2007-03-02 2011-06-20 Донг-А Фарм. Ко., Лтд. Новые кристаллические формы производных пирролилгептановой кислоты
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
WO2009090544A2 (en) * 2008-01-16 2009-07-23 Matrix Laboratories Limited Process for producing amorphous atorvastatin calcium

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
MXPA03003900A (es) * 2000-11-03 2005-02-17 Teva Pharma Forma vii de hemicalcio de atorvastatina.
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
PL367943A1 (en) * 2001-06-29 2005-03-07 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA2454500C (en) * 2001-07-30 2009-11-10 Dr. Reddy's Laboratories Ltd. Crystalline forms vi and vii of atorvastatin calcium

Also Published As

Publication number Publication date
WO2005090301A1 (en) 2005-09-29
AU2005223491A1 (en) 2005-09-29
EP1761489A1 (de) 2007-03-14
WO2005090301B1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
EP1727795B1 (de) Verfahren zur herstellung von atorvastatin-calcium in amorpher form
CA2560282A1 (en) Crystalline form of atorvastatin hemi calcium
US20090216029A1 (en) Process for the production of atorvastatin calcium in amorphous form
WO2013179300A2 (en) A process for the preparation of vildagliptin and its intermediate thereof
US9139527B2 (en) Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof
EP2172452A1 (de) Herstellung von kristallinem Atorvastatin-Magnesium
EP1732886B1 (de) Polymorphe von atorvastatin-tert.-butylester und deren verwendung als zwischenprodukte für die herstellung von atorvastatin
WO2017060885A1 (en) An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
CA2578722C (en) Process for atorvastatin calcium amorphous
EP2057151A2 (de) Verfahren zur reinigung von aprepitant
EP2075246A1 (de) Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
WO2007052296A2 (en) A process of preparing amorphous atorvastatin calcium
US20040242670A1 (en) Process for preparation of amorphous atorvastatin calcium
WO2006001026A1 (en) Irbesartan polymorphs
WO2006011155A1 (en) One pot process for amorphous atorvastain calcium
EP2373609A1 (de) Verwendung amphiphiler verbindungen zur kontrollierten kristallisation von statinen und statinzwischenprodukten
WO2008053312A2 (en) Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
WO2005033078A1 (en) Process for the production of atorvastatin calcium
WO2004069819A1 (en) Novel form of simvastatin.

Legal Events

Date Code Title Description
FZDE Dead